A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Bristol-Myers Squibb
Alterome Therapeutics, Inc.
Revolution Medicines, Inc.
Erasca, Inc.
Revolution Medicines, Inc.
PAQ Therapeutics, Inc.
Mirati Therapeutics Inc.
Eli Lilly and Company
Fate Therapeutics
Fate Therapeutics
NKGen Biotech, Inc.
R-Pharm
Eli Lilly and Company